Kalkine Media ASX Share Market News & Research
Watchlist Sign Up/Login
Kalkine Media ASX Share Market News & Research

What Does Leqselvi Launch Mean for Sun Pharma’s U S Ambitions?

1 min read | July 15, 2025 12:35 PM IST | By Team Kalkine Media

Recent News

thumbnail

Which Railway Stocks Could Double in the Coming Years?

thumbnail

Infosys and IT Stocks What Happens Next?

thumbnail

Can These EV Stocks Deliver Multibagger Returns?

thumbnail

India’s Economy Boom Time or Warning Signs Ahead?

Make Kalkine Media
My Trusted Source

Google Source

Sun Pharma has launched Leqselvi in the U.S., marking a major step in its global specialty drug strategy. After acquiring the asset and settling a patent dispute with Incyte, the 8 mg oral formulation is now prescribed for severe alopecia areata. Sales analysts anticipate $400 million in revenue by 2030 with peak sales potentially reaching $900 million. The settlement includes royalty terms and licensing arrangements, resolving U.S. patent litigation and enabling the launch. This adds depth to Sun Pharma’s dermatology and specialty pipeline and supports its shift from generics to innovative treatment areas. We’ll explore what it means for Sun’s financial outlook, competitive positioning in the U.S., and India’s profile as a global pharmaceutical innovator.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (Kalkine Media, we or us) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalised advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.